Kyung Nam Pharm Co.,Ltd.

A053950

KR7053950002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
1,420 ^KRW	+15.35%		+15.92%	-15.58%

2023	Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding	CI
2023	Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding	CI

Kyung Nam Pharm Co.,Ltd. agreed to acquire 9.94% stake in ILYA Co., Ltd from Kang, Jae Woo and Han, Seung Ja for KRW 7 billion.

March 14, 2023

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) agreed to acquire 9.94% stake in ILYA Co., Ltd (KOSDAQ:A058450) from Kang, Jae Woo and Han, Seung Ja for KRW 7 billion on March 15, 2023. The transaction is closed when the balance is paid, and the closing date is the date of the regular shareholders' meeting, March 31, 2023 or a date agreed upon by the contracting parties.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ENTERPARTNERS CO., LTD	4,850 KRW	-10.35%	+7.42%	42.64M
	KYUNG NAM PHARM CO.,LTD.	1,420 KRW	+15.35%	+15.92%	37.35M

Latest news about Kyung Nam Pharm Co.,Ltd.

Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding	21/09/23	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding	17/09/23	CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding	09/08/23	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding	16/07/23	CI
Kyung Nam Pharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Kyung Nam Pharm Co.,Ltd. agreed to acquire 9.94% stake in ILYA Co., Ltd from Kang, Jae Woo and Han, Seung Ja for KRW 7 billion.	14/03/23	CI
Enterpartners Co., LTD announced that it expects to receive KRW 26.599899939 billion in funding from Kyung Nam Pharm Co.,Ltd.	13/11/22	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 9.02379645 billion in funding from Blueberry NFT CO.,LTD.	23/12/21	CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 8 billion in funding from Metaplex Co., Ltd., and other investors	09/12/21	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 8 billion in funding from Metaplex Co., Ltd., and other investors	29/11/21	CI
Kyung Nam Pharm HealthCare Co.,Ltd. announced that it has received KRW 3.999997925 billion in funding from Blueberry NFT CO.,LTD., Kyung Nam Pharm Co.,Ltd.	19/07/21	CI
Kyung Nam Pharm HealthCare Co.,Ltd. announced that it expects to receive KRW 3.999997925 billion in funding from Blueberry NFT CO.,LTD., Kyung Nam Pharm Co.,Ltd.	11/07/21	CI
Kyung Nam Pharm Co.,Ltd., Virtualtek Corp and Ventage Partners Co., Ltd. agreed to acquire 9.32% stake in Livefinancial Co.,Ltd. for KRW 5.8 billion.	15/07/20	CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 1.9999997 billion in funding from KyungNam Biopharma CO.,LTD.	30/06/20	CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 14.5 billion in funding from Kartoon Korea CO.,LTD. and other investors	09/06/20	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 14.5 billion in funding from Kartoon Korea CO.,LTD. and other investors	03/06/20	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 1.9999997 billion in funding from BioGenetics CO.,LTD.	29/03/20	CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 20.49998703 billion in funding from BioGenetics CO.,LTD., Liveplex Co.,Ltd., CTGen Co.,Ltd., Widwin Investment Co., Ltd.	22/05/19	CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 6.49999411 billion in funding from BioGenetics CO.,LTD.	20/05/19	CI
BioGenetics CO.,LTD. acquired additional unknown stake in Kyung Nam Pharm Co.,Ltd. for KRW 22.5 billion.	12/05/19	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 20.49998703 billion in funding from BioGenetics CO.,LTD., Liveplex Co.,Ltd., CTGen Co.,Ltd., Widwin Investment Co., Ltd.	12/05/19	CI
Kyung Nam Pharm Co., Ltd. announced that it has received KRW 10.534998926 billion in funding	13/11/18	CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 6.499998976 billion in funding from BioGenetics CO.,LTD.	13/11/18	CI
Kyung Nam Pharm Co., Ltd. announced that it expects to receive KRW 16.99999501 billion in funding	14/10/18	CI
KMH Akyung Group cancelled the acquisition of unknown stake in Kyung Nam Pharm Co., Ltd..	28/06/18	CI

Chart Kyung Nam Pharm Co.,Ltd.

Duration

Period

More charts

Company Profile

KYUNG NAM PHARM.CO., LTD. is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The Company provides vitamin products under the brand name LEMONA. It supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KYUNG NAM PHARM CO.,LTD.	-15.58%	37.35M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals